Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Investing in nanotechnology

Nature Biotechnology volume 21, pages 1144–1147 (2003)Cite this article

The current commercial path for nanotechnology ventures mirrors the early evolution of the biotechnology industry, allowing similar strategies toward both technology commercialization and investment opportunities.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Trends in the patenting of nanotechnology.

©Bob Crimi

Figure 2: The increasing allure of nanotechnology to investors.

©Bob Crimi

Figure 3: Where is the money going?

©Bob Crimi

Figure 4: Cash flow patterns of life sciences companies.

©Bob Crimi

References

  1. Wolfe, J., Paull, R., & Hebert, P. The Nanotech Report 2003 (Lux Capital, New York, 2003).

    Google Scholar 

  2. Transcript of hearing before the subcommittee on courts, the internet and intellectual property, April 3, 2003, available at http://www.house.gov/judiciary/86267.pdf.

  3. Risinger, D., Boris, J., Li, B., & Calone, J. US Major Pharmaceutical Model and Pipeline Book, 4th Quarter 2002 Issue (Merrill Lynch, New York; 2003).

    Google Scholar 

Download references

Author information

Author notes

  1. Robert Paull, Josh Wolfe, Peter Hébert and Michael Sinkula: The authors are at Lux Capital, and Michael Sinkula is an associate at Lux Capital. Lux Capital is a venture capital firm focused on making early-stage investments in nanotechnology. A financial stipend was paid by Nature Biotechnology to Robert Paull for research on, and writing of, this article.

Authors and Affiliations

  1. 245 Park Avenue, 24th Floor, New York, 10167, NY, USA

    Robert Paull, Josh Wolfe, Peter Hébert & Michael Sinkula

Authors
  1. Robert Paull
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josh Wolfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Hébert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Sinkula
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paull, R., Wolfe, J., Hébert, P. et al. Investing in nanotechnology. Nat Biotechnol 21, 1144–1147 (2003). https://doi.org/10.1038/nbt1003-1144

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1003-1144

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing